It is well-established that intestinal microbiota and their metabolites exert a profound influence on human health and various kinds of disease conditions, such as cardiovascular, neurologic, endocrine, metabolic and digestive system diseases. However, the relationship between gut microbiota and urogenital diseases remains unclear. In particular, accumulating evidence indicated that the structure of gut microbiota is closely associated with urogenital diseases (e.g. lower urinary tract symptoms, urinary tract infections and prostate cancer). Furthermore, the important contribution of microbiota metabolites to human health and urogenital diseases is currently recognized (e.g. spermatogenesis, short-chain fatty acids promoting prostate cancer growth). Additionally, gut microbiota also affects the antitumor therapy by regulating the composition or the immune response (e.g. metastatic renal cell carcinoma patients receiving Anti-PD-L1 immune checkpoint inhibitors, Akkermansia muciniphila enriching in the gut of castrate-resistant prostate cancer patients with treatment of Abiraterone acetate, antibiotics influencing the clinical benefit of PD-1 based immunotherapy in patients with urothelial carcinoma). However, the exact molecular mechanism(s) through which the gut microbiota and their metabolites can influence the urogenital system remains unclear. The methods for clinical applications of gut microbiota would need to be further studied.
The purpose of this Research Topic is to establish an advanced platform for research on the contribution of gut microbiota and their metabolites in regulating urogenital diseases. This Research Topic will focus on animal experiments, cellular experiments, and clinical studies about the influence of gut microbiota (including bacteria, archaea, viruses, fungi and microeukaryotes in the gastrointestinal tract) on the urogenital system including benign and malignant diseases. To fully understand the potential relationship between gut microbiota and urogenital diseases, we are particularly interested in Original Articles and Reviews that focus on the mechanisms of the bidirectional gut-urogenital system axis in urogenital diseases. Furthermore, improvements in urogenital cancer diagnosis and new treatments are urgently needed. We believe that this topic will benefit clinical diagnosis and therapy of urogenital diseases in the future. Changes of intestinal microbiota and their metabolites in patients with genitourinary disorders.
We welcome subtopics on but not limited to:
• Associations of intestinal microbiota and their metabolites with the occurrence, development, and prognosis of genitourinary diseases (e.g., pathological staging, clinical grading, disease severity, prognosis, and other clinical indicators).
• Discovery of gut microbes’ biomarkers for the diagnosis or prognosis of urogenital diseases.
• The precise roles of certain gut microbiota species in the development and progression of urogenital diseases.
• The possible molecular mechanisms in modulating gut microbiota-urogenital diseases interactions.
• How does modulation of the gut microbes affect the treatment (such as immune checkpoint inhibitor, novel compounds, and new approaches) of urogenital diseases?
• In vitro and in vivo models to clarify the pathophysiological mechanisms of host and gut microbiota.
It is well-established that intestinal microbiota and their metabolites exert a profound influence on human health and various kinds of disease conditions, such as cardiovascular, neurologic, endocrine, metabolic and digestive system diseases. However, the relationship between gut microbiota and urogenital diseases remains unclear. In particular, accumulating evidence indicated that the structure of gut microbiota is closely associated with urogenital diseases (e.g. lower urinary tract symptoms, urinary tract infections and prostate cancer). Furthermore, the important contribution of microbiota metabolites to human health and urogenital diseases is currently recognized (e.g. spermatogenesis, short-chain fatty acids promoting prostate cancer growth). Additionally, gut microbiota also affects the antitumor therapy by regulating the composition or the immune response (e.g. metastatic renal cell carcinoma patients receiving Anti-PD-L1 immune checkpoint inhibitors, Akkermansia muciniphila enriching in the gut of castrate-resistant prostate cancer patients with treatment of Abiraterone acetate, antibiotics influencing the clinical benefit of PD-1 based immunotherapy in patients with urothelial carcinoma). However, the exact molecular mechanism(s) through which the gut microbiota and their metabolites can influence the urogenital system remains unclear. The methods for clinical applications of gut microbiota would need to be further studied.
The purpose of this Research Topic is to establish an advanced platform for research on the contribution of gut microbiota and their metabolites in regulating urogenital diseases. This Research Topic will focus on animal experiments, cellular experiments, and clinical studies about the influence of gut microbiota (including bacteria, archaea, viruses, fungi and microeukaryotes in the gastrointestinal tract) on the urogenital system including benign and malignant diseases. To fully understand the potential relationship between gut microbiota and urogenital diseases, we are particularly interested in Original Articles and Reviews that focus on the mechanisms of the bidirectional gut-urogenital system axis in urogenital diseases. Furthermore, improvements in urogenital cancer diagnosis and new treatments are urgently needed. We believe that this topic will benefit clinical diagnosis and therapy of urogenital diseases in the future. Changes of intestinal microbiota and their metabolites in patients with genitourinary disorders.
We welcome subtopics on but not limited to:
• Associations of intestinal microbiota and their metabolites with the occurrence, development, and prognosis of genitourinary diseases (e.g., pathological staging, clinical grading, disease severity, prognosis, and other clinical indicators).
• Discovery of gut microbes’ biomarkers for the diagnosis or prognosis of urogenital diseases.
• The precise roles of certain gut microbiota species in the development and progression of urogenital diseases.
• The possible molecular mechanisms in modulating gut microbiota-urogenital diseases interactions.
• How does modulation of the gut microbes affect the treatment (such as immune checkpoint inhibitor, novel compounds, and new approaches) of urogenital diseases?
• In vitro and in vivo models to clarify the pathophysiological mechanisms of host and gut microbiota.